John Lewicki
Chief Tech/Sci/R&D Officer at MEREO BIOPHARMA GROUP PLC
Net worth: 2 402 $ as of 2024-03-30
Profile
John A.
Lewicki is currently the Chief Scientific Officer at Mereo BioPharma Group Plc since 2020.
Prior to this, he worked at OncoMed Pharmaceuticals, Inc. as the President, Chief Executive Officer & Director from 2018 to 2019.
He also worked at Scios, Inc. as a Principal from 1983 to 2000.
Dr. Lewicki holds a doctorate degree from the University of California San Diego.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-24 | 3,640 ( 0.00% ) | 2 402 $ | 2024-03-30 |
John Lewicki active positions
| Companies | Position | Start |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Chief Tech/Sci/R&D Officer | 2020-06-30 |
Former positions of John Lewicki
| Companies | Position | End |
|---|---|---|
| ONCOMED PHARMACEUTICALS INC | Chief Executive Officer | 2019-04-22 |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Chief Tech/Sci/R&D Officer | - |
Training of John Lewicki
| University of California San Diego | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Private companies | 2 |
|---|---|
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
- Stock Market
- Insiders
- John Lewicki
